1 / 37

WHO, Geneva, Switzerland 18 november 2009

WHO, Geneva, Switzerland 18 november 2009. Alain PRAT, Technical adviser, MRS/TCM/HSS WHO - Geneva. Assessment of Medicines Regulatory Authorities (MRAs). Plan of the session. The assessment process The process approach The content of the assessment tool Some figures and outcomes.

Download Presentation

WHO, Geneva, Switzerland 18 november 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. WHO, Geneva, Switzerland18 november 2009 Alain PRAT, Technical adviser, MRS/TCM/HSS WHO - Geneva Assessment of Medicines Regulatory Authorities (MRAs)

  2. Plan of the session • The assessment process • The process approach • The content of the assessment tool • Some figures and outcomes

  3. Why an assessment tool ? • In line with one of the strategic objectives • To strengthen National Regulatory Authority's capacities • To assess in order to to identify strengths and weaknesses • To make recommendations on identified gaps for improvement • To propose/suggest supporting activities to satisfy the identified needs • To use assessment results as a tool for convincing decision-makers to obtain more support;

  4. Main steps of the assesssment / 1 • Expression of a need • Internal / External • Scope of the assessment • Objectives and expected outcomes • Assessment team • Qualification, experience, availability • Minimun 2 • Staff from the organization assessed • Preparation works • Request baseline information • Study of available information • Validation of the scope covered • Preparation of the assessment plan • Validation of the plan with the institution

  5. Main steps of the assessment / 2 • Opening session • Presentation of assessment team, objectives, methodology • Presentation of the authority • Conducting the visit • Follow planned activities, • Collection of evidence • Closing session • Presentation of the main findings and related recommendations • Presentation of the institutional plan • Closing remarks • Follow up • Provide for the draft report, collect the comments and finalize • Initiate/consider supportive actions

  6. Mapping the regulatory actors

  7. Mapping the processes / Historical findings based on 21 assessments

  8. Assessment methodology • Not based on impressions, feelings or any subjective considerations • Based on objective evidence • Evidence collected through interviews should, whenever possible, be confirmed by more objective means • Possible deficiencies or gaps should be thoroughly investigated and validated • Consensus should be reached at the end with auditees 

  9. Documented evidence • Interviewing personnel • Reviewing manuals, guidelines developped • Studying records • Reading reports • Scanning files or applications • Analyzing data, indicators • Observing activities performed and facilities where they are performed • Examining conditions during these activities

  10. Documented evidence • Investigations not only to check the presence or the absence of a document (law) • But to pursue to find the evidence on the implementation • And ideally the evidence that it provides the desire results….. • Examples : • Law has been issued and Regulation is missing • Law and regulation are published but no guidance is provided to applicants • Administratives procedures are established but no records are demonstrating its implementation • Administratives decisions are published but without any legal framework

  11. Mapping the processes / 1 • Ressources are input for the process • Results are the outputs of the process • Outputs from the process N • are inputs for the process N+1 • Outcomes are very often difficult to assess Structures/ Inputs Outputs Processes Outcomes

  12. Mapping the processes / 2 • Manage vision, mission, strategies, policies • Manage the ressources needed : human and others • Manage the relation with patient and customers • Manage the production of products and/or services • Manage supporting activities • Manage continuous improvement

  13. MRA is a process in itself Control Drug Promotion Quality Control Product Information Marketing authorization Regulatory Inspection Pharmaco vigilance Licensing Import Control Few business processes

  14. Recent improvement for the tool • Chapter on clinical trial developed • Chapter on vigilance aspects developed • New chapter on Narcotics • New chapter on International cooperation • Quality management system for NRAs • No more open question • All chapters reviewed and design consolidated

  15. Design of the assessment tool • Same format for each modules / functions • Legal basis, framework • Guideline and Documentation • Organisation and structure • Planning and internal procedures • Human and other Ressources • Records and others outputs • Availability of these information

  16. Chapters of the tool

  17. Institutional structure / 1 • Legal basis • Governance structure • Organization in place • Quality management system • Funding • Management of human resources

  18. Institutional structure / 2 • Independence and impartiality • Transparency and confidentiality • Management of committees and external expertise • Infrastructure and equipment • Monitoring and accountability • IT Management

  19. Marketing Authorization Equipments and facilities maintained Qualified personal Pertinent guideline SOP implemented Adequate legal framework Records Reception Evaluation Pre-Market Inspection Tests Comittee Planing and monitoring Application Decision MA + Ann. Assessment process

  20. Examples of key findings and gaps (Inspections) / 1 • Regulation • No regulations for compliance with good manufacturing practices (GMP) and good distribution practices (GDP) • Guideline • The available GMP guidelines are not updated to comply with WHO guidelines. • There are no Good Distribution, Storage or Wholesaling Practice Guidelines • Written official GMP guidelines do not exist at the moment except the unfinished draft • There is no official National GMP guideline and the WHO GMP guidelines have not been officially adopted, although they are being used

  21. Examples of key findings and gaps (Inspections) / 2 • Human resources • Lack of competency in GMP auditing • Limited human resources in GMP and GDP activities • Some of the staff have received limited but not adequate training in GMP inspection. They also lack experience. • There is no legal officer in the department. • The number and skills of inspectors is not adequate, considering the number of manufacturers to be inspected. • Independence/Impartiality • No code of conduct for inspectors • No provision or guidelines regarding conflict of interest of inspectors exist

  22. Examples of key findings and gaps (Inspections) / 3 • QMS and SOP • No periodicity defined for performing inspection and inadequate duration of inspection • No quality management system for inspectorate and in particular no documented procedure for documentation control, no internal periodic review or auditing • Documented procedure for planning, preparation, inspection and follow up not finalized • No procedure for qualification as inspector and inspection team leader • ProcedureS for follow up of deficiencies identified during inspections do not exist. • Written checklist and plans for inspection of manufacturers and distribution channels are not available.

  23. Examples of key findings and gaps (Inspections) / 4 • Equipment / IT • Limited access to the internet • Inadequate logistical support i.e. communication tools on the field, vehicles and computers • Organisation • Poor communication with the regional inspectors • No coordination or collaboration or exchange of information on inspection activities • No mechanism to demonstrate that all inspectors in the country follow the same procedure • Records and outcomes • No consolidated list of inspection activities performed

  24. Usefulness of indicators • Marketing Authorization • Number of application received, Number of MA delivered . • Time to acknoledge receipt of application ; • Time to deliver a MA ; • Time/delay to publish MA with related Product Information. • Inspection • Number of inspection • Time between two inspections ; • Time between initial inspection and follow up inspections (in case of non compliance)

  25. List of institutions to be visited and Personnel to be met / 1 • Ministry of Health / Ministry of industry, • Representatives of the Regulatory authority and any other organizations involved in the regulatory functions, • Staff of Regulatory authority or organization, • Representatives of the Industry Association of manufacturers, distributors, importers and exporters, • Representatives of the Professional Association of general practitioners, nurses and pharmacist, • Professionals councils (medical practitioners council, pharmacists council)

  26. List of institutions to be visited and Personnel to be met / 2 • Representatives of Consumers' associations, • Journalists. • Non-governmental associations • Procurement agencies, National medicines stores • Health research organizations • Chairmen or representatives of Advisory committee • Chairmen or representative of IRB / IEC • Representative of university academician

  27. Main source of documented evidence / 1 • Regulatory authority • Act, Law, Decree or circular establishing the Regulatory authority • Corporate, strategic and business plan of the NRA • Mission, vision, objectives and indicators of the NRA, i • Quality manual, • List of Internal procedure • List of internal forms and templates • List of the fees applicable for licensing, registration or authorization • Organigram/organization charts • Code of conduct/code of ethics • List of staff with their qualification • List of external experts • Annual report, self-assessment report

  28. Main source of documented evidence / 2 • Regulatory functions (Registration, Licensing, Inspection, Clinical Trail, Pharmaco-vigilance, Market control, Import Control, Quality Control Laboratory, control of drug promotion • Act, Law, Decree or circular establishing legal provisions for each regulatory functions • Guidance published on this domain • Internal procedure • List of equipment • Job descriptions • Decision, Authorization and their annexes

  29. Issuance of Recommandations • Based on the various life cycles of the activities needed such as : • To convince politicians • To change laws or decrees • To develop a guidance with consultative process • To reorganise and reshape the structure (centralized/decentralized activities) • To implement QMS, to develop procedures and planning • To manage HR • To change records • To implement communication strategy

  30. Guidance to use this tool • Regulatory assessment process • Main steps of a Regulatory assessment • Different categories of assessment in the time • Duration • General advice about assessment • For each regulatory function • Brief narrative description of the function • List of questions • Quantitative indicators of activities, of performances • Documented evidence to be reviewed (plan, procedures, reports, job descriptions, etc) • References to be consulted, based on WHO bibliography • Annexes • Templates

  31. MRA assessments worldwide • 44 Assessments performed on 40 Regulatory systems (with the involvement of HQ) • AFRO - 21 COUNTRIES / 24 ASSESSMENTS • EURO - 2 COUNTRIES / 2 ASSESSMENTS • EMRO - 4 COUNTRIES / 5 ASSESSMENTS • SEARO - 4 COUNTRIES / 4 ASSESSMENTS • WPRO - 7 COUNTRIES / 7 ASSESSMENTS • PAHO - 2 COUNTRIES / 2 ASSESSMENTS • WHO Regional assessments • ???? • Self-assessments • ???

  32. MRA assessments in AFRO region 2008 2007 2006 2004 2003 2003 No

  33. AFRO : Outcomes / Few examples • Publication of the main drug law

  34. AFRO : Outcomes / Few examples • Various kinds of MRAs

  35. AFRO : Outcomes / Few examples • Committees within the marketing authorization processes

  36. AFRO : Outcomes / Few examples • GMP requirements

  37. Thanks for your attention

More Related